Skip to main content

Table 1 Baseline characteristics of the control and HHcy groups

From: Hyperhomocysteinemia is associated with decreased apolipoprotein AI levels in normal healthy people

Parameters Control group (n = 1412) HHcy group (n = 356)
Age, y 41.11 ± 11.44 41.25 ± 12.25
Gender, Males/Females 790/622 196/160
BMI, kg/m2 24.33 ± 3.44 24.68 ± 3.13
SBP, mmHg 120.34 ± 11.26 121.35 ± 11.19
DBP, mmHg 73.04 ± 8.65 73.72 ± 8.89
TC, mmol/L 4.89 ± 0.90 4.87 ± 0.85
LDL-C, mmol/L 2.83 ± 0.73 2.90 ± 0.71
HDL-C, mmol/L 1.29 ± 0.32 1.18 ± 0.25**
TG, mmol/L 1.12 (0.76–1.71) 1.28 (0.88–1.97)**
apoAI, g/L 1.47 ± 0.25 1.38 ± 0.19**
apoB, g/L 0.87 ± 0.20 0.90 ± 0.20
FBG, mmol/L 5.34 ± 0.36 5.38 ± 0.35
FINS, μIU/mL 11.25 (7.40–16.16) 11.41 (8.39–16.40)
HOMA-IR 2.68 (1.74–3.87) 2.72 (1.97–4.01)
Homocysteine, μmol/L 11.04 ± 1.81 26.53 ± 13.68**
  1. Data are means ± SD unless indicated otherwise. TG, FINS and HOMA-IR are shown as median and range. HHcy: hyperhomocysteinemia; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; TG: triglyceride; apoAI: apolipoprotein AI; apoB: apolipoprotein B; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance. * significantly different at P < 0.05 vs control; ** significantly different at P < 0.01 vs control